Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|ClinicalTrials.gov Identifier: NCT00005100|
Recruitment Status : Unknown
Verified December 2003 by National Center for Research Resources (NCRR).
Recruitment status was: Recruiting
First Posted : April 7, 2000
Last Update Posted : June 24, 2005
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay (IRMA) in patients with acromegaly and normal volunteers.
II. Measure the levels of IGF-I and its binding protein, IGFBP-3, in these cohorts.
III. Determine any correlation between levels of IGF-I and IGFBP-3 and GH suppressibility as assessed by sensitive IRMA.
IV. Determine if patients who demonstrate biochemical features of mild GH excess are at risk for progression to active disease.
|Condition or disease|
PROTOCOL OUTLINE: Blood samples are collected and assessed for growth hormone and IGF-I by polyclonal radioimmunoassay (RIA) and immunoradiometric assay (IRMA). Growth hormone is measured at baseline and 60, 90, and 120 minutes after a 100 g glucose drink. Serum glucose is measured at baseline and at 2 hours post dextrose administration by the glucose hexokinase method.
Clinical scores are determined for headache, perspiration, fatigue, joint pain, and acne.
Exams and tests may be repeated every 6 months for 2 years.
|Study Type :||Observational|
|Enrollment :||165 participants|
|Study Start Date :||September 1999|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005100
|United States, New York|
|Columbia University College of Physicians and Surgeons||Recruiting|
|New York, New York, United States, 10032|
|Contact: Pamela U. Freda 212-305-3725|
|Study Chair:||Pamela U. Freda||Columbia University|